Arachidonic acid metabolites, the eicosanoids, are key mediators of allergen-induced airway inflammation and remodeling in asthma. The availability of free arachidonate in cells for subsequent eicosanoid biosynthesis is controlled by phospholipase A 2s (PLA 2s), most notably cytosolic PLA 2-α. 10 secreted PLA 2s (sPLA 2s) have also been identified, but their function in eicosanoid generation is poorly understood. We investigated the role of group X sPLA 2 (sPLA 2-X), the sPLA 2 with the highest in vitro cellular phospholipolysis activity, in acute and chronic mouse asthma models in vivo. The lungs of sPLA 2-X −/− mice, compared with those of sPLA 2-X +/+ littermates, had significant reduction in ovalbumin-induced infiltration by CD4 + and CD8 + T cells and eosinophils, goblet cell metaplasia, smooth muscle cell layer thickening, subepithelial fibrosis, and levels of T helper type 2 cell cytokines and eicosanoids. These data direct attention to sPLA 2-X as a novel therapeutic target for asthma.